AMAC American Medical Alert Corp. (MM)

Glancy Binkow & Goldberg LLP is continuing its investigation of potential claims against the Board of Directors of American Medical Alert Corp. (“American Medical” or the “Company”) (Nasdaq:AMAC) related to the proposed acquisition of the Company by Tunstall Healthcare Group Limited. The transaction is valued at approximately $80 million or $8.55 per share.

The investigation concerns whether the Board of Directors of American Medical breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Its share price has sky rocketed from $5.00 on December 2, 2010 to $6.15 on January 10, 2011. Additionally, it appears that certain officers and directors of the Company have secured prestigious post-merger positions with the Company. For example, Jack Rhian will continue to serve as President and CEO of the post-merger Company.

If you are a shareholder of American Medical, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1801 Avenue of the Stars, Suite 311, Los Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by email to shareholders@glancylaw.com.

American Medical Alert (NASDAQ:AMAC)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

American Medical Alert (NASDAQ:AMAC)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024